MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-13-2026
Country |
 USA |
IPO year |
1983 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
538 M |
Market Cap[1] |
$ 187 B |
EBITDA (LTM) |
$ 12.4 B |
P/E (LTM) |
26.25 |
P/S (LTM) |
7.06 |
EPS (LTM) |
13.25 |
Amgen is a biopharmaceutical company founded in the USA in 1980. The company is engaged in the development and production of drugs for the treatment of serious diseases such as cancer, rheumatoid arthritis, and osteoporosis.
AMGN is a leading provider of biotechnology products and has over 20,000 employees worldwide. The company has operations in over 100 countries and produces its products in facilities around the world.
The main goal of Amgen is to improve the lives of patients by developing innovative drugs that help fight serious illnesses. The company invests billions of dollars annually in research and development to find new treatment options.
AMGN also advocates for sustainability and environmental protection. The company is committed to reducing its CO2 emissions and making its production processes as environmentally friendly as possible. Amgen is also involved in the community and supports various programs to improve healthcare and education.
Overall, Amgen is an innovative and responsible company dedicated to developing new treatment options for serious illnesses while also striving to protect the environment and support the community.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Benitec Biopharma
BNTC
|
$ 10.98 | -4.52 % | $ 452 M | Nasdaq Capital Market | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 221.88 | -0.87 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Milestone Pharmaceuticals
MIST
|
$ 1.36 | -20.0 % | $ 45.5 M | Nasdaq Global Select Market |  Canada |
 |
Pharming Group N.V.
PHAR
|
$ 15.36 | -0.71 % | $ 7.59 B | Nasdaq Global Select Market |  Niderland |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Inventiva S.A.
IVA
|
$ 5.78 | -4.3 % | $ 138 M | Nasdaq Global Market | France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Tiziana Life Sciences PLC
TLSA
|
$ 1.21 | -3.97 % | $ 71.5 M | Nasdaq Global Market |  Britain |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
PainReform Ltd.
PRFX
|
$ 2.28 | -0.44 % | $ 1.03 M | Nasdaq Capital Market |  Israel |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Assembly Biosciences
ASMB
|
$ 28.46 | 3.45 % | $ 319 M | Nasdaq Global Select Market,SPB | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.37 | -4.2 % | $ 350 M | Nasdaq Global Select Market | Britain |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Axsome Therapeutics
AXSM
|
$ 156.92 | -1.23 % | $ 7.81 B | Nasdaq Global Market,SPB | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
AbCellera Biologics
ABCL
|
$ 3.4 | -3.68 % | $ 1.02 B | Nasdaq Global Select Market | Canada |
 |
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
BioMarin Pharmaceutical
BMRN
|
$ 54.13 | -1.64 % | $ 10.4 B | Nasdaq Global Select Market,SPB | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | USA |
 |
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | USA |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | USA |
 |
Compugen Ltd.
CGEN
|
$ 2.09 | -0.95 % | $ 195 M | Nasdaq Global Market,SPB | Israel |
 |
Coherus BioSciences
CHRS
|
$ 1.52 | -5.59 % | $ 178 M | Nasdaq Global Market | USA |
 |
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | USA |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Burford Capital Limited
BUR
|
$ 7.7 | -5.87 % | $ 1.29 B | NYSE | Britain |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 8.6 | -3.8 % | $ 115 M | Nasdaq Global Market | USA |
 |
Curis
CRIS
|
$ 0.77 | 1.89 % | $ 4.86 M | Nasdaq Global Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.